Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Impact · against what's priced in

The data provides biological plausibility for extending lorundrostat's application into heart failure, creating a potential long-term growth lever beyond the core hypertension indication. However, the immediate valuation driver remains the December 22, 2026, PDUFA date.

MLYS+0.40

No priced-in read yet